Clinical Trials
Allergan and Ironwood Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide Colonic Release-2 (CR2)
Ronwood Pharmaceuticals and Allergan plc announced topline data from a Phase IIb clinical trial evaluating an investigational linaclotide colonic release-2 (CR2) formulation in adult patients...
Clinical Trials
Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases
Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, and OSE Immunotherapeutics SA announced the signing...
Clinical Trials
Genfit says FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC
GENFIT a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the...
Clinical Trials
Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity
Spark Therapeutics and Pfizer Inc announced that Lindsey A. George, M.D a hematologist and attending physician at the Children’s Hospital of Philadelphia and lead investigator...
Clinical Trials
Achilles Teutics launched with funds of £13.2 million to develop Immunotherapies for Cancer
SYNCONA LLP and CANCER RESEARCH TECHNOLOGY (CRT) announce the formation of Achilles Therapeutics Ltd .The new private company will bring together world-class research from UCL...
Clinical Trials
Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan
Thermo Fisher Scientific, the world leader in serving science announced the expansion of its Fisher BioServices cryogenic service capabilities in Japan. This...
Clinical Trials
Sun Pharma announces the Phase 3 results of investigational psoriasis medicine
Sun Pharma has announced late-breaking data from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) achieving the primary endpoint with tildrakizumab, an investigational IL-23p19...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.